Table of Contents: IAVI Report

VAX is the bulletin on AIDS vaccine research and news intended for a broad audience, ranging from policymakers and community leaders to advocates and vaccine trial volunteers. Each issue features a collection of articles written in an easily-accessible style allowing non-technical readers to understand the latest developments in the science and policy of AIDS vaccine research.

The Vax bulletin is available in

English (HTML and PDF),

Chinese (PDF),

Deutsch (PDF),

Français (PDF),

Español (PDF), and

Português (PDF).

VAX 2008 Nov; 6(12)

SPOTLIGHT: An Interview with Alan Bernstein
GLOBAL NEWS: Two Prime-Boost Regimens Enter Clinical Trials
PRIMER: Understanding Innate Immunity and HIV: What role do innate immune responses play in defending against HIV infection?

VAX 2008 Nov; 6(11)

SPOTLIGHT: PrEP Work
GLOBAL NEWS: IAVI Opens AIDS Vaccine Laboratory in New York City
PRIMER: Understanding Approaches to Inducing Neutralizing Antibodies: What are some of the novel approaches researchers are exploring to induce broadly neutralizing antibodies against HIV?

VAX 2008 Oct; 6(10)

SPOTLIGHT: Researchers STEP up to the challenge
GLOBAL NEWS: New neutralizing antibody research center established
GLOBAL NEWS: Nobel Prize awarded for discovery of HIV
PRIMER: Understanding Animal Models of HIV Infection: What are the limitations of the animal models used by researchers to evaluate AIDS vaccine candidates?

VAX 2008 Sep; 6(9)

SPOTLIGHT: Individual armor against HIV
GLOBAL NEWS: Brazilian government renews HIV Vaccine Plan
GLOBAL NEWS: New network to focus on gender and HIV
PRIMER: Understanding Control of Virus Replication: What can researchers learn from studying how some species of nonhuman primates can control infection with SIV?

VAX 2008 Aug; 6(8)

SPOTLIGHT: HIV prevention relay race
GLOBAL NEWS: AIDS Vaccine Blueprint launched: A challenge to the field
GLOBAL NEWS: Passage of PEPFAR
PRIMER: Understanding the Genetic Variation of HIV: What are the implications of the genetic diversity of HIV for AIDS vaccine development?

VAX 2008 Jul; 6(7)

SPECIAL ISSUE: AIDS 2008: A changing landscape for vaccine research

VAX 2008 Jun; 6(6)

SPOTLIGHT: Nearing a decision on PAVE
GLOBAL NEWS: Coordinated action on TB and HIV
PRIMER: Understanding Live-Attenuated Vaccines: What can AIDS vaccine researchers learn from live-attenuated SIV vaccines?

VAX 2008 May; 6(5)

SPOTLIGHT: A static epidemic
GLOBAL NEWS: World AIDS Vaccine Day commemorated
PRIMER: Understanding the Recruitment of Volunteers at Risk of HIV Infection: Why are volunteers who are at high risk of HIV infection necessary participants in late-stage AIDS vaccine trials?

VAX 2008 Apr; 6(4)

SPOTLIGHT: Balancing the AIDS vaccine budget
GLOBAL NEWS: HIV Vaccines: Progress and Prospects
GLOBAL NEWS: First Phase I trial of Ad26 vector begins
PRIMER: Understanding Cellular Immune Responses: What is known about cellular immune responses against HIV?

VAX 2008 Mar; 6(3)

SPOTLIGHT: When it rains... it pours
GLOBAL NEWS: Addressing the challenges of HIV prevention trials
PRIMER: Understanding the Recruitment and Retention of Women in Clinical Trials: What are some of the considerations regarding recruitment and retention of women in AIDS vaccine clinical trials?

VAX 2008 Feb; 6(2)

SPOTLIGHT: Small loans: Big hopes
GLOBAL NEWS: Trial results presented at CROI
PRIMER: Understanding Biostatistics and the STEP Trial: How are statisticians analyzing the data from the STEP trial?

VAX 2008 Jan; 6(1)

SPOTLIGHT: Exploring mucosal protection for a mucosal virus
GLOBAL NEWS: Cutting Progress?
PRIMER: Understanding HIV Transmission: What events lead to the sexual transmission of HIV and how can mucosal immune responses protect against infection?

IAVI Report

IAVI Report is a publication on international AIDS vaccine research published bi-monthly by the International AIDS Vaccine Initiative (IAVI).

IAVI Report 2008 Nov/Dec; 12(6)

HIV Transmission: The genetic bottleneck: Researchers are finally getting a handle on the nature of the virus that is transmitted and establishes infection, offering promising hints for AIDS vaccine development
PrEP Work: If effective, pre-exposure prophylaxis for HIV will offer many opportunities, but also numerous challenges
Mucosal Vaccines: Insights from different fields: Researchers are joining forces to understand mucosal immunity and develop mucosal vaccines
An Interview with Alan Bernstein: At the Helm of the Global HIV Vaccine Enterprise
Research Briefs: Prime-Boost Regimen with Ad26 Offers Renewed Hope for T-cell Vaccines
Vaccine Briefs: IAVI Opens AIDS Vaccine Laboratory in New York City

IAVI Report 2008 Sep/Oct; 12(5)

AIDS Vaccine Researchers STEP Up to the Challenge: Questions linger, but so does determination, as researchers gather at the AIDS Vaccine 2008 Conference
Mighty Mice: Scientists are still improving the humanized mouse model but are optimistic about its future role in evaluating AIDS vaccine candidates
An Interview with Stanley Plotkin: The state of the field
Research Briefs: Apobec3 may restrict retroviral infection by controlling antibody response
Vaccine Briefs: New center focuses on neutralizing antibodies; Nobel awarded for discovery of HIV

IAVI Report 2008 Jul/Aug; 12(4)

HIV prevention research: The relay race continues: Researchers gathered at the International AIDS Conference focused on long-term efforts to control the spread of HIV
PAVEing the way to a smaller trial: A smaller, more focused trial is now under consideration at NIAID to replace the proposed PAVE 100 study
Individual armor against HIV: Individuals who have an apparent resistance to HIV infection may hold important clues for AIDS vaccine research, but solving the mystery of this resistance is extremely complex
Engineering immunity: Researchers are developing new approaches to introduce genes for antibodies as a novel way to protect against HIV infection
Vaccine Briefs: AIDS Vaccine Blueprint launched: A challenge to the field

IAVI Report 2008 May/Jun; 12(3)

Go forth and multiply: AIDS vaccine researchers are turning their focus from replication-deficient viral vectors to potentially more efficacious replication-competent approaches
A static epidemic: New estimates show that public health efforts in the US have had little success controlling the number of new HIV infections over time
Small loans: Big hopes: Can economic empowerment programs give women the skills and power to reduce their risk of HIV?
Research Briefs: Study shows role of Th17 cells
Vaccine Briefs: World AIDS Vaccine Day and HIV discovery commemorated; Super sequencing

IAVI Report 2008 Mar/Apr; 12(2)

Down, but not out: At the first Keystone meeting on HIV vaccines following the STEP trial, researchers discuss recalibrating research and development priorities
Balancing AIDS vaccine research: Leading AIDS vaccine researchers gather to discuss balancing AIDS vaccine funding
The great barrier: Understanding mucosal immune responses is critical to developing effective AIDS vaccines, but progress has been slow
Vaccine Briefs: Some candidate microbicides can damage epithelia; IOM report addresses the challenges of HIV prevention trials; Microbicide trials update

IAVI Report 2008 Jan/Feb; 12(1)

Clues from CROI: The 15th Annual meeting had its share of sobering news from clinical trials, but researchers also reported many exciting advances
Scanning the scientific horizon: An array of fundamental developments in understanding HIV infection and pathogenesis, and the interpretation of immune responses against the virus, headlined this year's CROI meeting
Perspective: Conducting HIV prevention research in South Africa: Challenges of and successes in conducting HIV research in KwaZulu-Natal, the epicenter of the South African HIV epidemic
Cooking up candidates: Safety is key when manufacturing candidate AIDS vaccines for clinical trials, and this involves a costly manufacturing process
Vaccine Briefs: Trial results presented at CROI; Circumcision progress?

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©2008. AEGiS.